Project Grant R01AI187065
Award Date
7/9/25
Completion Date
6/30/29
Dollars Obligated
$3.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This Project Grant award, valued at $792,687.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural features of sialoglycans necessary for influenza A virus (IAV) infection and adaptation across various host species. The key activities under this award include: 1) using CRISPR/Cas9 techniques to truncate different types of sialoglycans in human lung...
This Cooperative Agreement awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,352,292 in funding to the University of Illinois to conduct high-resolution profiling and computational modeling of influenza virus-immune dynamics during natural infection. The key objectives are to: (1) identify reliable immune correlates of reduced viral shedding and transmission risk, and...
This Project Grant award of $438,500.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, San Diego (UCSD). The primary objectives of this research project are to: Identify the sequence interface regulating interactions between the influenza A virus (IAV) protein NS2 and the viral polymerase, using a high-throughput mutation approach. Explore preliminary...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,170,096.00 to New York University School of Medicine to develop and optimize a peptide inhibitor of influenza virus splicing for broad-spectrum antiviral therapy. The key objectives are: (1) investigating the mechanism of action of the L7AE protein on various Orthomyxoviridae family members, (2) characterizing a transgenic mouse...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $560,178 Project Grant to the University of Wisconsin - Madison. The goal of this 5-year grant, which runs from Jul 25, 2025 to Jun 30, 2030, is to understand the dynamics of the interaction between Staphylococcus aureus bacteriophages, the bacteria, and the mammalian host. Specifically, the research aims to elucidate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $605,778 to The Ohio State University to elucidate how influenza A viruses (IAV) manipulate the cellular protein ARIH2 to promote viral replication in airway epithelial cells. The research aims to uncover ARIH2 as a novel IAV restriction factor exploited by the virus, and evaluate ARIH2's potential as a therapeutic...
This Project Grant award of $422,814 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research at the University of Wisconsin-Madison to develop and apply adversarial machine learning methods to predict the risk of animal viruses spilling over into humans. The key objectives are to: (i) consider the spillover risk of viral sequence variants, rather than just static sequences; (ii) characterize and explain the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $433,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The funding supports research to investigate the role of the influenza A virus (IAV) protein PB1-F2 in causing hypoxemia (low blood oxygen levels) and acute respiratory distress syndrome (ARDS) in influenza infections. The research aims to define the effects of PB1-F2 on alveolar type II (ATII)...
This Project Grant award of $734,184 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to elucidate the mechanisms of parainfluenza virus genome replication. The primary awardee, Trustees of Boston University, will conduct structure-guided analysis of the viral polymerase complex to understand how it regulates the balance between transcription and replication. The team will also investigate how viral...
This federal Project Grant award of $692,689 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to advance understanding of pegivirus persistence and immune control. The primary research objectives are to: Determine the adaptive immune functions responsible for "semi-control" of mouse-adapted pegivirus (MAPGV) infection in wild-type mice. This will involve using immune gene-knockout mice and lymphocyte...